Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Cardiora

Cardiora?uq=8lCq2teR
PRIVATE STATUS
Early Stage VC LATEST DEAL TYPE
$4.15M LATEST DEAL AMOUNT
1 INVESTORS
Description

Developer of an oral drug designed to prevent heart failure. The company's oral drug is a CRD-102 compound that has functional outcomes with ensured safety, enabling patients to avail improve quality of life and reduced hospital re-admission rates.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Primary Office
  • Level 9, 278 Collins Street
  • Melbourne, Victoria 3000
  • Australia

+61 (03) 0000 0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Cardiora’s full profile, request a free trial.

Cardiora Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 23-Nov-2015 $4.15M 00.000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Cardiora Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Brandon Capital Partners Venture Capital Minority 000 0000 000000 0

Cardiora Executive Team (2)

Name Title Board
Seat
Contact
Info
Bob Soh MD Chief Operating Officer
David Kaye Ph.D Founder & Board Member

Cardiora Board Members (4)

Name Representing Role Since Contact
Info
Chris Nave Ph.D Brandon Capital Partners Board Member 000 0000
David Kaye Ph.D Cardiora Founder & Board Member 000 0000
Guy Krippner Ph.D Cardiora Board Member 000 0000
Ingmar Wahlqvist Brandon Capital Partners Board Member 000 0000